Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.

[1]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[2]  I. Kline,et al.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study , 2018, JAMA oncology.

[3]  K. Ballman,et al.  Somatic mutations precede acute myeloid leukemia years before diagnosis , 2018, Nature Medicine.

[4]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[5]  Chieh-Yu Liu,et al.  Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[6]  R. Collins,et al.  Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML) , 2017 .

[7]  A. Abujamra,et al.  DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2017, Disease markers.

[8]  R. Bejar,et al.  Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS , 2017, Current Hematologic Malignancy Reports.

[9]  P. Vyas,et al.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.

[10]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[11]  Hua Yang,et al.  AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. , 2017, Cancer discovery.

[12]  L. Pleyer,et al.  Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications , 2016, Journal of Hematology & Oncology.

[13]  H. Kantarjian,et al.  IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression , 2015, Leukemia.

[14]  V. Visconte,et al.  Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease , 2014, Blood research.

[15]  P. Fenaux,et al.  Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure , 2013, Haematologica.

[16]  B. Ko,et al.  The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. , 2012, Blood.

[17]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[18]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Kantarjian,et al.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. , 2011, Seminars in oncology.

[20]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[23]  J. Issa,et al.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.

[24]  J. Esteve,et al.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. , 2009, Blood.

[25]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[26]  Yu Shen,et al.  Myelodysplastic syndrome is not merely "preleukemia". , 2002, Blood.

[27]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[28]  A. Tefferi,et al.  Myelodysplastic syndromes. , 2009, The New England journal of medicine.

[29]  F. Appelbaum,et al.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. , 2000, Blood.